Erratum to: Ann Hematol (2013) 92:443–449
DOI 10.1007/s00277-012-1648-2
We have to report that in subsequent studies performed on the same patient cohort investigated for ERG expression in this article, we by chance found that in 7 out of 86 patients the PML/RARA-fusion transcript could not be detected. The reason for this discrepancy with the original diagnostic findings remains unclear. However, repeating our analyses on the remaining cohort of 79 securely PML/RARA-positive APL patients we could confirm our previously reported findings regarding ERG expression levels and prognosis: High expression of ERG (≥75th percentile) in APL patients is associated with an inferior relapse free survival (RFS: 43 % vs 78 % for ERGlow after 10 years of follow-up; p=0.004) and an inferior relapse free interval (RFI: 74 % vs. 97 % after 10 years of follow-up; p=0.003). The overall survival of responders to induction therapy was 62 % in the ERGhigh group compared to 81 % in the ERGlow group. However, as reported before, this difference did not yield statistical significance (p=0.11).
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at doi:10.1007/s00277-012-1648-2.
Rights and permissions
About this article
Cite this article
Hecht, A., Nowak, D., Nowak, V. et al. Erratum to: High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia. Ann Hematol 93, 1447 (2014). https://doi.org/10.1007/s00277-014-2101-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-014-2101-5